D4.6 Report on the results of cycle 3 demonstrators:Aggregates internal deliverables ID4.12, ID4.13, ID4.14, ID4.15, ID4.16

Hernández-Leo, D., Sligte, H., Glahn, C., Krekels, B., Keuls, C., Louys, A., Stefanov, K., Perez, M., Chacón, J., Santos, P., Mazzetti, A., Herder, E., Maxwell, K., Kiercheben, J., Griffiths, D., & Kluijfhout, E. (2009). D4.6 - Report on the results of cycle 3 demonstrators. Aggregates internal deliverables ID4.12, ID4.13, ID4.14, ID4.15, ID4.16. TENCompetence.This document includes the evaluation results of the Cycle 3 real-life evaluation activities. A cross-analysis of the results is compiled in order to present the impact indicators of the project in terms of outreach, learning benefits, organizational implications, and business opportunities identified in these experiences. The implementations and eight business/market-relevant demonstrators conducted in collaboration with external "adopter organizations" from different countries in Europe. These external organizations are Associated Partners or different units within the partners'organization. The revised pilots and the demonstrators test the tooling achieved along DIP-3. Both pilots and business demonstrators show to provide benefits to socially- and industrially-relevant scenarios. Areas of proven special impact include adult competence developmentfor social inclusion, provision of learning paths to support competence development of distributed professionals, informal competence development, human resources personal competence development, and sharing of competence profiles between organizations to support the mobility of their professionals.The work on this publication has been sponsored by the TENCompetence Integrated Project that is funded by the European Commission's 6th Framework Programme, priority IST/Technology Enhanced Learning. Contract 027087 [http://www.tencompetence.org

D10.2 – Research Data Management Plan, version 3.0:RAGE – WP10 – D10.2

What data will be collected, processed or generated during the RAGE project? Following what methodology and standards? And what data will be shared and/or made openly available, and how will it be curated and preserved? These issues are typically described in a Data Management Plan (DMP), outlining how research data is handled during the project and after the project is completed. The RAGE DMP specifically provides guidelines on ethics, data protection and open research data access to RAGE researchers involved in WP5 (Case experiments) and WP8 (Validation). Ethics and data protection are especially relevant in view of the games and audiences targeted by RAGE. Therefore, RAGE is one of the participating projects in the EU open research data pilot, an initiative under Horizon 2020 that aims at improving and maximising the access to and re-use of research data created in European projects.This document is the third and final iteration of the DMP

Explaining variation in Down's syndrome screening uptake: comparing the Netherlands with England and Denmark using documentary analysis and expert stakeholder interviews.

Background: The offer of prenatal Down’s syndrome screening is part of routine antenatal care in most of Europe; however screening uptake varies significantly across countries. Although a decision to accept or reject screening is a personal choice, it is unlikely that the widely differing uptake rates across countries can be explained by variation in individual values alone. The aim of this study was to compare Down’s syndrome screening policies and programmes in the Netherlands, where uptake is relatively low ( 90% respectively), in an attempt to explain the observed variation in national uptake rates. Methods: We used a mixed methods approach with an embedded design: a) documentary analysis and b) expert stakeholder analysis. National central statistical offices and legal documents were studied first to gain insight in demographic characteristics, cultural background, organization and structure of healthcare followed by documentary analysis of primary and secondary sources on relevant documents on DSS policies and programme. To enhance interpretation of these findings we performed in-depth interviews with relevant expert stakeholders. Results: There were many similarities in the demographics, healthcare systems, government abortion legislation and Down’s syndrome screening policy across the studied countries. However, the additional cost for Down’s syndrome screening over and above standard antenatal care in the Netherlands and an emphasis on the ‘right not to know’ about screening in this country were identified as potential explanations for the ‘low’ uptake rates of Down’s syndrome screening in the Netherlands. The social context and positive framing of the offer at the service delivery level may play a role in the relatively high uptake rates in Denmark. Conclusions: This paper makes an important contribution to understanding how macro-level demographic, social and healthcare delivery factors may have an impact on national uptake rates for Down’s syndrome screening. It has suggested a number of policy level and system characteristics that may go some way to explaining the relatively low uptake rates of Down’s syndrome screening in the Netherlands when compared to England and Denmark

(18)F-Fluorocholine PET-CT enables minimal invasive parathyroidectomy in patients with negative sestamibi SPECT-CT and ultrasound : A case report

INTRODUCTION: Primary hyperparathyroidism is a common endocrine disorder for which the primary treatment is surgery. For minimal invasive parathyroidectomy adequate pre-operative imaging is essential. Conventional imaging is often inconclusive. There are reports that (18)F-fluorocholine PET-CT might be a superior imaging modality, however evidence is still very scarce. This is the first report of a case with negative ultrasound and sestamibi SPECT-CT imaging that underwent successful minimal invasive surgery because of (18)F-fluorocholine PET-CT. PRESENTATION OF CASE: A 57 year-old man presented to us with complaints of fatigue. Laboratory results showed a biochemical primary hyperparathyroidism and an additional DEXA-scan revealed osteopenia of the lumbar spine. Conventional imaging consisting of neck ultrasound and Tc-99m-sestamibi SPECT-CT was however unable to localize the pathological gland. Subsequent (18)F-fluorocholine PET-CT did clearly localize an adenoma dorsally of the left thyroid lobe which was removed at that exact location using minimal invasive parathyroidectomy. Histological examination confirmed the diagnosis adenoma and calcium levels remained normal at follow-up. DISCUSSION: There is clinical need for a superior imaging modality to detect pathological parathyroid glands to enable minimal invasive surgery. (18)F-Fluorocholine is widely available. CONCLUSION: (18)F-Fluorocholine PET-CT is a promising new imaging modality for localizing parathyroid adenomas and enabling minimal invasive parathyroidectomy when conventional imaging fails to do. Clinicians should consider its use as a second line modality for optimal patient care